Exploring Therapeutic Targets of the Beta Amyloid Pathway to Slow the Progression of Alzheimer Disease

https://www.pharmacytimes.org/on-demand/exploring-therapeutic-targets-of-the-beta-amyloid-pathway-to-slow-the-progression-of-alzheimer-disease

Related Videos

Related Content

Advertisement

December 24th 2024

Research Supports Need for Diversity in Hemophilia Trials and Reducing Resource Strain

Giuliana Grossi

The high health care burden faced by individuals with hemophilia underscores the urgent need for innovative treatments and improved diversity in clinical trials.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

December 24th 2024

Top 5 Multiple Myeloma Content of 2024

Maggie L. Shaw

Through interviews and articles infused with expert insight, progress against this cancer that develops in the bone marrow was showcased.

December 19th 2024

Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma

Giuliana Grossi

Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.

December 24th 2024

Top 5 Most-Read Mental Health Articles of 2024

Giuliana Grossi

The most-read articles addressing mental health in 2024 spanned therapeutic advancements, research discoveries, and insight into enhanced practice guidelines.

December 23rd 2024

First Subcutaneous Prophylaxis for Hemophilia A and B With Inhibitors Approved by FDA

Giuliana Grossi

The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with inhibitors by preventing or reducing bleeding episodes in adults and children 12 years and older.

Related Content

Advertisement

December 24th 2024

Research Supports Need for Diversity in Hemophilia Trials and Reducing Resource Strain

Giuliana Grossi

The high health care burden faced by individuals with hemophilia underscores the urgent need for innovative treatments and improved diversity in clinical trials.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

December 24th 2024

Top 5 Multiple Myeloma Content of 2024

Maggie L. Shaw

Through interviews and articles infused with expert insight, progress against this cancer that develops in the bone marrow was showcased.

December 19th 2024

Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma

Giuliana Grossi

Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.

December 24th 2024

Top 5 Most-Read Mental Health Articles of 2024

Giuliana Grossi

The most-read articles addressing mental health in 2024 spanned therapeutic advancements, research discoveries, and insight into enhanced practice guidelines.

December 23rd 2024

First Subcutaneous Prophylaxis for Hemophilia A and B With Inhibitors Approved by FDA

Giuliana Grossi

The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with inhibitors by preventing or reducing bleeding episodes in adults and children 12 years and older.